β Blockers in heart failure: a comparison of a vasodilating β blocker with metoprolol

Objective To determine whether a third generation vasodilating β blocker (celiprolol) has long term clinical advantages over metoprolol in patients with chronic heart failure. Design A double blind placebo controlled randomised trial. Setting University teaching Hospital. Patients 50 patients with s...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Heart (British Cardiac Society) 1998-01, Vol.79 (1), p.86-92
Hauptverfasser:	Sanderson, J E, Chan, S K W, Yu, C M, Yeung, L Y C, Chan, W M, Raymond, K, Chan, K W, Woo, K S
Format:	Artikel
Sprache:	eng
Schlagworte:	Adrenergic beta-Antagonists - therapeutic use Aged Analysis of Variance Biological and medical sciences Cardiovascular system celiprolol Celiprolol - therapeutic use Chi-Square Distribution Double-Blind Method Electrocardiography, Ambulatory Exercise Test Female Follow-Up Studies heart failure Heart Failure - drug therapy Heart Failure - mortality Heart Failure - physiopathology Humans Male Medical sciences metoprolol Metoprolol - therapeutic use Middle Aged Pharmacology. Drug treatments Statistics, Nonparametric Treatment Outcome Vasodilator agents. Cerebral vasodilators β blockers
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Objective To determine whether a third generation vasodilating β blocker (celiprolol) has long term clinical advantages over metoprolol in patients with chronic heart failure. Design A double blind placebo controlled randomised trial. Setting University teaching Hospital. Patients 50 patients with stable chronic heart failure (NYHA class II-IV) due to idiopathic dilated, ischaemic, or hypertensive cardiomyopathy, with left ventricular ejection fraction
ISSN:	1355-6037 1468-201X
DOI:	10.1136/hrt.79.1.86